Literature DB >> 2088187

Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.

D Gargallo-Viola1, M Esteve, M Moros, R Coll, M A Xicota, C de Andres, R Roser, J Guinea.   

Abstract

E-4502, E-4501, E-4500, E-4480, E-4474, and E-4441 are new monofluorinated or difluorinated quinolone agents that are chemically characterized by the presence of an azetidin ring, with different C'-3 substituents, at position 7 of the molecular structure. The MICs of the difluorinated compounds E-4501, E-4474, and E-4441 for 90% of isolates were 0.06 to 1, 0.06 to 1, and 0.12 to 1 microgram/ml, respectively, against gram-positive organisms (staphylococci, streptococci, and Enterococcus faecalis); 0.0015 to 0.12, 0.015 to 0.12, and 0.03 to 0.12 microgram/ml, respectively, against members of the family Enterobacteriaceae except Providencia spp.; and 1, 1, and 2 micrograms/ml, respectively, against Pseudomonas aeruginosa. E-4501, E-4474, and E-4441 inhibited all anaerobic bacteria at concentrations of 1, 2, and 4 micrograms/ml, respectively. Difluorinated compounds were significantly more active than the corresponding monofluorinated analogs E-4502, E-4500, and E-4480 against aerobic and facultatively anaerobic organisms, as well as against anaerobes. Considering monofluorinated and difluorinated compounds, activity in moderate ascending order was observed in quinolones containing an amine and a methyl group (E-4441 and E-4480), an amine group (E-4474 and E-4500), and a methylamine group (E-4501 and E-4502) in the C'-3 position of the azetidin ring. E-4501, E-4474, and E-4441 were more active than norfloxacin and DR-3355 [S-(-)-ofloxacin], had activities comparable to or slightly lower than that of ciprofloxacin against gram-negative bacteria, and were more active than all the reference quinolones against gram-positive organisms and anaerobes. E-4502 and E-4501, which were used to determine the effect of pH, were less active in acidic medium. In general, E-4502, E-4501, E-4500, E-4480, E-4474, and E-4441 activities were not affected or increased in medium containing serum but decreased in the presence of 10 mM Mg2+ or in human urine at pH 5.5. The protective effect of E-4501, E-4474, and E-4441 after oral administration against systemic infections with Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa in mice was greater than that of ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2088187      PMCID: PMC172054          DOI: 10.1128/AAC.34.12.2318

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

Review 1.  Structure-activity relationships of the fluoroquinolones.

Authors:  D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

2.  In vitro activity of DR-3355, an optically active ofloxacin.

Authors:  T Une; T Fujimoto; K Sato; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

3.  A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria.

Authors:  P B Fernandes; D T Chu; R N Swanson; N R Ramer; C W Hanson; R R Bower; J M Stamm; D J Hardy
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

4.  In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.

Authors:  R Wise; J M Andrews; J P Ashby; R S Matthews
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

5.  Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.

Authors:  D Gargallo; M Moros; R Coll; M Esteve; J Parés; M A Xicota; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

6.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

7.  In vitro activity of PD 127,391, an enhanced-spectrum quinolone.

Authors:  R Wise; J P Ashby; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

8.  [A new synthetic antibacterial : 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1, 4-dihydroquinolin-3-carboxylic acid (1589 R.B.)].

Authors:  Y Goueffon; G Montay; F Roquet; M Pesson
Journal:  C R Seances Acad Sci III       Date:  1981-01-05

9.  Conditions affecting the results of susceptibility testing for the quinolone compounds.

Authors:  S M Smith; R H Eng; C E Cherubin
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more
  9 in total

1.  In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.

Authors:  D Gargallo-Viola; M Esteve; S Llovera; X Roca; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Antibacterial activity and pharmacokinetics of four new 7-azetidinyl fluoroquinolones.

Authors:  R Coll; D Gargallo-Viola; E Tudela; M A Xicota; S Llovera; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

3.  Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent.

Authors:  D Gargallo-Viola; S Ferrer; E Tudela; M Robert; R Coll; R Roser; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

4.  Comparative activities of eight quinolones against members of the Bacteroides fragilis group.

Authors:  M V Borobio; M Conejo; E Ramirez; A I Suarez; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

5.  In vitro evaluation of E-4695, a new fluoro-naphthyridine.

Authors:  R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

6.  In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.

Authors:  J Guinea; M Robert; D Gargallo-Viola; M A Xicota; J Garcia; E Tudela; M Esteve; R Coll; M Pares; R Roser
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

7.  In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds.

Authors:  M S Barrett; R N Jones; M E Erwin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-02       Impact factor: 3.267

8.  E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens.

Authors:  J Guinea; D Gargallo-Viola; M Robert; E Tudela; M A Xicota; J Garcia; M Esteve; R Coll; M Pares; R Roser
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 9.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.